LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics^® discovery platform, today announced that management will participate in the following investor conferences in September 2024:

• Morgan Stanley 22^nd Annual Global Healthcare Conference (New York, NY) on Wednesday, September 4, 2024 – Qasim Rizvi, Chief Executive Officer and Micah Benson, Ph.D., Chief Scientific Officer, to take part in fireside chat scheduled at 7:45 a.m. ET.
  
  
• BofA Healthcare Trailblazers Private Company Conference (Boston, MA) on Wednesday, September 25, 2024.
  

About KSQ Therapeutics

KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ's proprietary CRISPRomics^® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. For more information, please visit  www.ksqtx.com and follow us on LinkedIn and X.

Media Contact:

Cory Tromblee
cory@scientpr.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.